Mr. Hugh Rogers reports

BIONXT ANNOUNCES NON-BROKERED PRIVATE PLACEMENT OF UNITS PURSUANT TO THE LISTED ISSUER EXEMPTION

Bionxt Solutions Inc. has arranged a non-brokered private placement of units of the company at a price of 33 cents per unit, for maximum aggregate gross proceeds of up to approximately $2-million pursuant to the listed issuer financing exemption available under Part 5A of National Instrument 45-106 (Prospectus Exemptions). Pursuant to the LIFE offering, the company will issue up to a maximum of 6,060,606 units at a price of 33 cents per unit for maximum gross proceeds of up to approximately $2-million. There is no minimum offering. There is an offering document relating to the offering that can be accessed under the company's profile at SEDAR+ and at the Bionxt website. Prospective investors should read this offering document before making an investment decision. The securities offered under the LIFE offering will not be subject to a hold period in accordance with applicable Canadian securities laws.

Each unit will be composed of one common share in the capital of the company and one share purchase warrant. Each warrant will entitle the holder thereof to acquire one additional share at a price of 50 cents per warrant share until the date that is 24 months from the closing date of the LIFE offering.

In connection with the offering, the company will pay finders' fees of up to 6.0 per cent of the gross proceeds raised by the company from the sale of units to subscribers directly introduced to the company by eligible finders. In addition, the company will issue to eligible finders non-transferable finders' warrants of up to 6.0 per cent of the number of units sold in the offering. Each finder's warrant will entitle the holder to purchase one share at an exercise price of 50 cents for a period of 24 months from the date of issuance.

The offering is expected to close before July 27, 2026.

The company intends to use the proceeds raised from the offering for conducting its European research and development and operations and for working capital and general corporate purposes.

Closing of the offering is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including that of the Canadian Securities Exchange. The company may, at its discretion, elect to close the offering sooner and/or in one or more tranches.

About Bionxt Solutions Inc.

Bionxt is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems and active pharmaceutical ingredient development. The company's proprietary platforms -- sublingual (thin film), transdermal (skin patch) and oral (enteric-coated tablets) -- target key therapeutic areas, including autoimmune diseases, neurological disorders and longevity. With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. Bionxt is committed to improving health care by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide. Bionxt is listed on the Canadian Securities Exchange (BNXT) and trades in Germany under WKN: A3D1K3.

We seek Safe Harbor.